Worldwide Corporate Headquarters
929 North Front Street
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.
380 articles with PPD
This recognition affirms the excellence and dedication of PPD® Laboratories professionals in helping advance clients’ antibody-drug conjugate (ADC) research to develop new anticancer therapies.
Enhancing immunochemistry, biomarker and chromatography services for biopharma clients
Evidera and CSS Collaborate to Develop Joint Real-world and Patient-centered Research Capabilities in Japan
Evidera, a business unit of Pharmaceutical Product Development, LLC (PPD), has entered into an exclusive collaboration agreement with Clinical Study Support, Inc. (CSS), a subsidiary of Shin Nippon Biomedical Laboratories Ltd. (SNBL), extending both organizations’ capabilities to deliver more robust consulting and analytical capabilities and creating a more complete geographic customer solution for clinical, real-world and patient-centered research.
First-patient-in milestone achieved in only two weeks with Cancer Treatment Centers of America
Strong site relationships key to quality execution, on-time delivery for biopharmaceutical customers
The recognition follows PPD’s inclusion earlier this year on Forbes’ list of America’s Best Employers for Diversity.
Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.
Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization dedicated to improving health, has been named to Forbes magazine’s 2019 list of America’s Best Employers for Diversity
Jing Tu has been selected as the 2018 winner of the Bioanalysis Rising Star Award, selected from among 30 nominees across the globe.
Award recognizing PPD’s commitment to innovation for advancing and accelerating the drug development process.
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.
Expanding Global Oncology Testing for Clinical Trials
Substantially Increases Ability to Support Large Molecule Development
Provides Personalized Support for Patients and Enhances Retention for Clients
Pharmaceutical Product Development, LLC (PPD) today announced it has been honored for employee learning and development programs that help the global contract research organization deliver service excellence to its pharmaceutical and biotechnology clients.
PPD today announced that Maria Teresa Hilado, chief financial officer of Allergan, has been named to PPD’s board of directors.
The companies will jointly support pediatric drug development for clients from concept to market launch through a unique end-to-end service that will speed delivery of pediatric medicines.
Hill is the chairman, chief executive officer and co-founder of GNS Healthcare, a leading precision medicine company.
PPD has terminated a number of employees in its HR department, but has provided few details about the job cuts, according to reports.
PPD today announced it was awarded a seven-year contract under the Clinical Research Support Services program of the Division of AIDS, NIAID, part of the NIH.